Tinnitus — a persistent ringing, buzzing, or hissing in the ears — affects millions of people worldwide, often disrupting sleep, focus, and overall quality of life. Despite its prevalence, effective treatments have remained elusive for many sufferers, leaving them searching for relief in a sea of sound therapies, medications, and lifestyle changes. That’s where the Lenire device comes in — a revolutionary, non-invasive treatment for tinnitus sufferers.
The Lenire device is one of the latest treatments for tinnitus, offering a clinically proven, non-invasive solution for individuals struggling with persistent ear ringing or buzzing. Developed by Neuromod Devices and approved by regulatory bodies including the U.S. FDA, Lenire is designed to help reduce the severity and impact of tinnitus symptoms over time.
While Lenire tinnitus therapy has shown positive results for many users, there have been isolated reports of individuals experiencing a temporary worsening of symptoms. In rare cases, some users have noted an increase in tinnitus intensity during or shortly after beginning treatment.
However, these experiences are not common and may be influenced by individual variability, underlying conditions, or incorrect usage of the device. Clinical trials have generally reported a high rate of safety and tolerability, with most participants experiencing either improvement or no change in symptoms.
As with any medical treatment, it’s important to consult with a qualified audiologist or ENT specialist to determine if Lenire is appropriate for your specific case and to monitor your response throughout the therapy.
The Lenire tinnitus device is for sale in multiple countries, including the USA and Australia, and is now available in Denmark, where it has recently launched as part of expanded access to innovative tinnitus therapies.
The cost varies depending on the clinic and country, but most treatment programs range between $4,000 and $6,000 USD. This typically includes the device itself, initial assessments, a personalized treatment plan, and follow-up appointments with a certified audiologist. In the USA, some clinics—such as those in American Fork, UT, and Spanish Fork, UT — offer financing options, with monthly payments starting around $375/month over a 12-month period.
✅ Clinically validated with strong results from large-scale trials
✅ Non-invasive, drug-free, and safe for long-term use
✅ FDA-approved and supported by audiology professionals
✅ Customizable therapy tailored to individual hearing profiles
✅ Many users report long-lasting relief even after treatment ends
❌ High cost (typically $4,000–$6,000 USD) and not usually covered by insurance
❌ Mixed results since some users experience little to no improvement
❌ Requires consistent daily use over several weeks
❌ Limited availability in certain regions and clinics
In March 2023, the U.S. Food and Drug Administration (FDA) granted De Novo approval to the Lenire device, making it the first bimodal stimulation device authorized for the treatment of tinnitus in the United States. The FDA classified Lenire as a Class II medical device, intended for adults aged 18 and older who suffer from at least moderate tinnitus. This milestone not only validates over a decade of research by Neuromod devices but also opens the door for broader access to a safe, non-invasive therapy for millions of Americans living with tinnitus.
Compared to traditional tinnitus treatments such as sound therapy, hearing aids, or cognitive behavioral therapy (CBT), the Lenire device offers a more advanced and targeted approach.
Traditional tinnitus treatments like sound therapy and hearing aids aim to mask the perception of tinnitus or improve hearing loss that may be contributing to it. While these methods can offer temporary relief, they don’t address the neurological causes of tinnitus.
In contrast, Lenire tinnitus therapy uses bimodal neuromodulation to actively retrain the brain’s response to tinnitus, offering a more targeted and potentially longer-lasting solution.
Cognitive behavioral therapy is a psychological approach that helps patients manage the emotional and psychological impact of tinnitus. It’s effective in reducing distress, anxiety, and depression related to the condition, but it doesn’t reduce the tinnitus itself.
Lenire complements CBT by directly targeting the auditory system, offering a physical intervention that can reduce the intensity of tinnitus, while CBT supports emotional coping.
The Lenire device is an FDA-approved tinnitus treatment that uses bimodal neuromodulation — sound and tongue stimulation — to reduce tinnitus symptoms.
The Susan Shore device, developed at the University of Michigan, also uses bimodal stimulation but targets a specific brainstem region involved in tinnitus. Its stimulation is more precisely timed and delivered to the neck or cheek, aiming for more targeted neurological effects.
Yes, Lenire can be used in conjunction with the other tinnitus treatments mentioned above. This opens the door to combination treatment strategies that may enhance overall effectiveness and provide more comprehensive relief for individuals with tinnitus. However, it’s important for patients to consult with a healthcare professional to ensure that any combined approach is tailored to their specific condition and needs.
It's time to finally treat your hearing loss. Sign up for a free consultation with a licensed hearing care professional today to determine if you have hearing loss. It’s the start of your journey towards better hearing.
EarPros benefits:
